Pharmaceutical products
Original notice title
Germany-Hamburg: Pharmaceutical products
Opportunity Score
Why this score?
Opportunity
65 / 100
Complexity
40 / 100
Risk factors
The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...
No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Beschaffer: Bundesministerium für Wirtschaft und Energie (BMWE), Beschafftungsdienstleister: Forschungszentrum Jülich GmbH, Projektträger Jülich (PtJ)
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Oct 31, 2026
Overview
Strong opportunityKey Facts
- Supplies contract
- 3 lots
- Supply of pharmaceutical products under non-exclusive discount agreements for specified active substances.
- Agreements aim to bridge the period between patent expiry and exclusive discount contracts.
Show full summary
Open house procedure for non-exclusive discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for pharmaceutical products. The notice is a voluntary transparency notice, not a public procurement subject to EU directives. The procedure is open to all qualified pharmaceutical entrepreneurs, with contracts awarded to all who meet the requirements. The contract runs from 1 November 2023 to 31 October 2026, with a possible 6-month extension. Ten lots cover various active substances. No estimated value is provided. Submission of participation and contract documents is electronic via the portal, with continuous accession possible during the contract term.
Risks
The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...
No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...
No procurement documents available
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Administrative
- Participation is open to pharmaceutical entrepreneurs (as defined in §4 Abs. 18 AMG) who submit a declaration of suitability and reliability.
- Bid submission via electronic portal; documents must be submitted with qualified electronic signature or signed original.
- For timely inclusion of discount pricing in pharmacy software, complete documents must be received by the 3rd of the month prior to the desired start month.
Requirements may be incomplete.
Buyer
Location
Karlsruhe, DEU
Website
Activity
Defence
Lots (3)
01
Carbamazepine (RET, N1, N2, N3) - TK, HEK, hkk
Discount agreement for Carbamazepine in specified forms, for participating health insurance funds TK, HEK, and hkk.
Category
Deadline
02
Ciclosporin (WKA) - TK, HEK, hkk
Discount agreement for Ciclosporin in specified form, for TK, HEK, hkk.
Category
Deadline
03
Levothyroxine sodium (excluding WKA, LSE, TRO, ILO) - TK
Discount agreement for Levothyroxine sodium in specified forms, for TK only.
Category
Deadline
Procurement Details
- Publication date
- 19 Sep 2023
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 566780-2023
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
65 / 100
Complexity
40 / 100
Risk factors
The procedure is a voluntary transparency notice, not a public contract under EU directives. Bidders have no procuremen...
No estimated value or guaranteed volume means uncertain revenue. Discounts may be substantial and profitability depends...
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications